Connect with us
Compass Pathways (NASDAQ: CMPS) deepened its financial losses to $155.1 million in 2024 as the company nears a big milestone for its experimental psilocybin therapy, with...
Red Light Holland (CSE: TRIP) (OTCQB: TRUFF) reported a 9.5% slide in third-quarter revenue Wednesday, as the Ontario-based psychedelics company faced challenges including lower mushroom sales...
The state of Colorado awarded its first-ever psilocybin-related licenses to prospective business owners, kickstarting what could be a major new therapeutic industry, directly in the wake...
Numinus Wellness (TSX: NUMI) (OTCQX: NUMIF) informed investors after the markets closed on Friday that it plans to wind down certain non-operating subsidiaries as part of...
Atai Life Sciences (NASDAQ: ATAI) announced after the markets closed on Wednesday that it priced a registered underwritten offering to raise approximately $55 million. Shares rose...
Clinical-stage biotech Cybin Inc. (NYSE: CYBN) reported a net loss of $10.5 million for its fiscal third quarter ending Dec. 31, but highlighted progress in its...
GH Research PLC (Nasdaq: GHRS) has launched an underwritten public offering in the United States of $150 million of ordinary shares. The company said in its offering document...
A day after executing a reverse stock split to maintain its Nasdaq listing, Enveric Biosciences (NASDAQ: ENVB) raised $5 million Thursday through a public offering, sending...
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) raised nearly C$1 million in fresh capital as it continues to expand production internationally. The psychedelics supplier...
Psychedelic drug treatment companies are racing to find a cure for alcohol use disorder or alcoholism. This week, atai Life Sciences gave investors an update on...
